Format

Send to

Choose Destination
J Clin Endocrinol Metab. 2014 May;99(5):E876-80. doi: 10.1210/jc.2013-3633. Epub 2014 Jan 16.

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.

Author information

1
Diabetes Center (Y.Z., L.Y., Y.X., L.L., G.H., Z.L., X.L., Z.Z.), Institute of Metabolism and Endocrinology, The Second Xiangya Hospital and Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan 410011, People's Republic of China; Department of Diabetes and Metabolic Medicine (R.D.L.), Blizard Institute, London E1 2AT, United Kingdom; and Division of Endocrinology, Metabolism, and Nutrition (X.W.), Rutgers University-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903.

Abstract

CONTEXT:

Dipeptidyl peptidase 4 (DPP-4) inhibitors have been widely used in type 2 diabetes. An important unanswered question concerns the effect of DPP-4 inhibition on β-cell function in patients with autoimmune diabetes.

OBJECTIVE:

The objective of the study was to investigate the effects of the DPP-4 inhibitor on β-cell function in patients with recent-onset latent autoimmune diabetes in adults (LADA).

DESIGN AND SETTING:

This study was an open-label, randomized-controlled study conducted in the Department of Endocrinology at the Second Xiangya Hospital.

PATIENTS AND INTERVENTION:

Thirty recently diagnosed LADA patients were randomized 1:1 to receive insulin therapy with 100 mg/d sitagliptin (group A, n = 15) or without sitagliptin (group B, n = 15) for 12 months.

MAIN OUTCOME MEASURES:

Fasting and 2-hour postprandial blood samples were obtained at baseline and after 3, 6, 9, and 12 months of treatment to determine blood glucose, glycosylated hemoglobin, and C-peptide levels.

RESULTS:

There were no differences in the clinical baseline data between the two groups. During the 12 months of follow-up, there were no significant differences in glucose and glycosylated hemoglobin levels between the two groups. At 12 months, fasting C-peptide (FCP), 2-hour postprandial C-peptide (CP), and ΔCP (ΔCP = 2 h CP-FCP) levels were not different in group A (P > .05) compared with baseline, whereas in group B the levels of FCP, 2-hour CP and ΔCP were significantly decreased compared with baseline (P < .05). Levels of 2-hour CP were higher in group A than group B at 12 months (P < .05).

CONCLUSIONS:

LADA patients treated with sitagliptin and insulin maintained β-cell function by comparison with insulin alone.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT01159847.

PMID:
24432999
DOI:
10.1210/jc.2013-3633
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center